Can EPS Development be Avoided with Early Interventions? The Potential Role of Tamoxifen

Abstract

Background

Encapsulating peritoneal sclerosis (EPS) is a severe complication of peritoneal dialysis (PD). Identification of patients at high risk for EPS (“EPS-prone”) and delivery of appropriate interventions might prevent its development. Our aim was to evaluate the clinical characteristics and outcomes of all EPS and EPS-prone patients diagnosed at our PD unit.

Methods

For a 30-year period representing our entire PD experience, we retrospectively identified all patients with EPS (diagnosed according to International Society for Peritoneal Dialysis criteria) and all patients defined as EPS-prone because they met at least 2 established criteria (severe peritonitis, PD vintage greater than 3 years, severe hemoperitoneum, overexposure to glucose, and acquired ultrafiltration failure).

Results

Of 679 PD patients, we identified 20 with EPS, for an overall prevalence of 2.9%. Mean age at diagnosis was 50.2 ± 16.4 years, with a median PD time of 77.96 months (range: 44.36 – 102.7 months) and a median follow-up of 30.91 months (range: 4.6 – 68.75 months). Of patients with EPS, 10 (50%) received tamoxifen, 10 (50%) received parenteral nutrition, and 2 (10%) underwent adhesiolysis, with 25% mortality related to EPS. Another 14 patients were identified as EPS-prone. Median follow-up was 54.05 months (range: 11.9 – 87.04 months). All received tamoxifen, and 5 (36%) received corticosteroids; none progressed to full EPS. We observed no differences in baseline data between the groups, but the group with EPS had been on PD longer (84 ± 53 months vs 39 ± 20 months, p = 0.002) and had a higher cumulative number of days of peritoneal inflammation from peritonitis (17.2 ± 11.1 days vs 9.8 ± 7.9 days, p = 0.015). Overall mortality was similar in the groups. The incidence of EPS declined during our three decades of experience (5.6%, 3.9%, and 0.3%).

Conclusions

Being a serious, life-threatening complication of PD, EPS requires high suspicion to allow for prompt diagnosis and treatment. Early detection of EPS-prone states and delivery of appropriate intervention might prevent EPS development. Tamoxifen seems to be a key strategy in prevention, but caution should be used in interpreting our results. Additional randomized controlled studies are needed.

Keywords

Encapsulating peritoneal sclerosis EPS EPS-prone states peritonitis tamoxifen

Get full access to this article

View all access options for this article.

References

Gandhi

V.C.

, Humayun

H.M.

, Ing

T.S.

, Daugirdas

J.T.

, Jablokow

V.R.

, Iwatsuki

Sclerotic thickening of the peritoneal membrane in maintenance peritoneal dialysis patients.

Arch Intern Med 1980; 140: 1201–3.

Nakamoto

Encapsulating peritoneal sclerosis—a clinician's approach to diagnosis and medical treatment.

Perit Dial Int 2005; 25(Suppl 4): S30–8.

Korte

, Sampimon

, Betjes

, Krediet

Encapsulating peritoneal sclerosis: the state of affairs.

Nat Rev Nephrol 2011; 7: 528–38.

Habib

S.M.

, Betjes

M.G.

, Fieren

M.W.

, Boeschoten

E.W.

, Abrahams

A.C.

, Boer

W.H.

Management of encapsulating peritoneal sclerosis: a guideline on optimal and uniform treatment.

Neth J Med 2011; 69: 500–7.

Kawaguchi

, Kawanishi

, Mujais

, Topley

, Oreopoulos

D.G.

Encapsulating peritoneal sclerosis: definition, etiology, diagnosis, and treatment. International Society for Peritoneal Dialysis Ad Hoc Committee on Ultrafiltration Management in Peritoneal Dialysis.

Perit Dial Int 2000; 20(Suppl 4): S43–55.

Korte

M.R.

, Habib

S.M.

, Lingsma

, Weimar

, Betjes

M.G.

Posttransplantation encapsulating peritoneal sclerosis contributes significantly to mortality after kidney transplantation.

Am J Transplant 2011; 11: 599–605.

Fieren

M.W.

, Betjes

M.G.

, Korte

M.R.

, Boer

W.H.

Posttransplant encapsulating peritoneal sclerosis: a worrying new trend?

Perit Dial Int 2007; 27: 619–24.

Kawanishi

, Kawaguchi

, Fukui

, Hara

, Imada

, Kubo

Encapsulating peritoneal sclerosis in Japan: a prospective, controlled, multicenter study.

Am J Kidney Dis 2004; 44: 729–37.

Balasubramaniam

, Brown

E.A.

, Davenport

, Cairns

, Cooper

, Fan

S.L.

The Pan-Thames EPS study: treatment and outcomes of encapsulating peritoneal sclerosis.

Nephrol Dial Transplant 2009; 24: 3209–15.

10.

Brown

M.C.

, Simpson

, Kerssens

J.J.

, Mactier

on behalf of the Scottish Renal Registry. Encapsulating peritoneal sclerosis in the new millennium: a national cohort study. Clin J Am Soc Nephrol 2009; 4: 1222–9.

11.

Lee

H.Y.

, Kim

B.S.

, Choi

H.Y.

, Park

H.C.

, Kang

S.W.

, Choi

K.H.

Sclerosing encapsulating peritonitis as a complication of long-term continuous ambulatory peritoneal dialysis in Korea.

Nephrology (Carlton) 2003; 8(Suppl): S33–9.

12.

Nomoto

, Kawaguchi

, Kubo

, Hirano

, Sakai

, Kurokawa

Sclerosing encapsulating peritonitis in patients undergoing continuous ambulatory peritoneal dialysis: a report of the Japanese Sclerosing Encapsulating Peritonitis Study Group.

Am J Kidney Dis 1996; 20: 420–7.

13.

Summers

A.M.

, Clancy

M.J.

, Syed

, Harwood

, Brenchley

P.E.

, Augustine

Single-center experience of encapsulating peritoneal sclerosis in patients on peritoneal dialysis for end-stage renal failure.

Kidney Int 2005; 68: 2381–8.

14.

Johnson

D.W.

, Cho

, Livingston

B.E.

, Hawley

C.M.

, McDonald

S.P.

, Brown

F.G.

Encapsulating peritoneal sclerosis: incidence, predictors, and outcomes.

Kidney Int 2010; 77: 904–12.

15.

Herrero

J.C.

, Molina

, Lentisco

, García

, Ortiz

, Mon

Sclerosing encapsulating peritonitis: a latent threat. Changes of posture in surgical treatment [Spanish].

Nefrologia 2007; 27: 729–36.

16.

Nomoto

, Kawaguchi

, Kubo

, Hirano

, Sakai

, Kurokawa

Sclerosing encapsulating peritonitis in patients undergoing continuous ambulatory peritoneal dialysis: a report of the Japanese Sclerosing Encapsulating Peritonitis Study Group.

Am J Kidney Dis 1996; 28: 420–7.

17.

Gayomali

, Hussein

, Cameron

S.F.

, Protopapas

, Finkelstein

F.O.

Incidence of encapsulating peritoneal sclerosis: a single-center experience with long-term peritoneal dialysis in the United States.

Perit Dial Int 2011; 31: 279–86.

18.

Korte

M.R.

, Sampimon

D.E.

, Lingsma

H.F.

, Fieren

M.W.

, Looman

C.W.

, Zietse

on behalf of the Dutch Multicenter EPS Study. Risk factors associated with encapsulating peritoneal sclerosis in Dutch EPS study. Perit Dial Int 2011; 31: 269–78.

19.

Sampimon

D.E.

, Korte

M.R.

, Barreto

D.L.

, Vlijm

, de Waart

, Struijk

D.G.

Early diagnostic markers for encapsulating peritoneal sclerosis: a case–control study.

Perit Dial Int 2010; 30: 163–9.

20.

Brown

E.A.

, Van Biesen

, Finkelstein

F.O.

, Hurst

, Johnson

D.W.

, Kawanishi

Length of time on peritoneal dialysis and encapsulating peritoneal sclerosis: position paper for ISPD.

Perit Dial Int 2009; 29: 595–600.

21.

Imai

, Nakamoto

, Fukushima

, Yamanouchi

, Ishida

, Suzuki

Glucocorticoid protects against the development of encapsulating peritoneal sclerosis on peritoneal dialysis.

Adv Perit Dial 2002; 18: 124–30.

22.

Martins

L.S.

, Rodrigues

A.S.

, Cabrita

A.N.

, Guimaraes

Sclerosing encapsulating peritonitis: a case successfully treated with immunosuppression.

Perit Dial Int 1999; 19: 478–81.

23.

Mori

, Matsuo

, Sutoh

, Toriyama

, Kawahara

, Hotta

A case of a dialysis patient with sclerosing peritonitis successfully treated with corticosteroid therapy alone.

Am J Kidney Dis 1997; 30: 275–8.

24.

Korte

M.R.

, Fieren

M.W.

, Sampimon

D.E.

, Lingsma

H.F.

, Weimar

, Betjes

on behalf of the investigators of the Dutch Multicentre EPS Study. Tamoxifen is associated with lower mortality of encapsulating peritoneal sclerosis: results of the Dutch Multicentre EPS Study. Nephrol Dial Transplant 2011; 26: 691–7.

25.

Evrenkaya

T.R.

, Atasoyu

E.M.

, Unver

, Basekim

, Baloglu

, Tulbek

M.Y.

Corticosteroid and tamoxifen therapy in sclerosing encapsulating peritonitis in a patient on continuous ambulatory peritoneal dialysis.

Nephrol Dial Transplant 2004; 19: 2423–4.

26.

Thirunavukarasu

, Saxena

, Anijeet

, Pai

, Wong

C.F.

Encapsulating peritoneal sclerosis presenting with recurrent ascites and tamoxifen: case reports and review of the literature.

Ren Fail 2007; 29: 775–6.

27.

Kawanishi

, Watanabe

, Moriishi

, Tsuchiya

Successful surgical management of encapsulating peritoneal sclerosis.

Perit Dial Int 2005; 25(Suppl 4): S39–47.

28.

Kawanishi

, Moriishi

, Tsuchiya

Experience of 100 surgical cases of encapsulating peritoneal sclerosis: investigation of recurrent cases after surgery.

Adv Perit Dial 2006; 22: 60–4.

29.

Kawanishi

, Ide

, Yamashita

, Shimomura

, Moriishi

, Tsuchiya

Surgical techniques for prevention of recurrence after total enterolysis in encapsulating peritoneal sclerosis.

Adv Perit Dial 2008; 24: 51–5.

30.

Kawanishi

, Shintaku

, Moriishi

, Dohi

, Tsuchiya

Seventeen years’ experience of surgical options for encapsulating peritoneal sclerosis.

Adv Perit Dial 2011; 27: 53–8.

31.

Selgas

, Fernandez–Reyes

M.J.

, Bosque

, Bajo

M.A.

, Borrego

, Jimenez

Functional longevity of the human peritoneum: how long is continuous peritoneal dialysis possible? Results of a prospective medium long-term study.

Am J Kidney Dis 1994; 23: 64–73.

32.

Raderson

D.H.

, Farrel

Mass transfer properties of human peritoneum.

ASAIO J 1980; 3: 140–6.

33.

Krediet

The peritoneal membrane in chronic peritoneal dialysis patients.

Kidney Int 1999; 55: 341–56.

34.

Siato

Peritoneal dialysis in Japan: the issue of encapsulating peritoneal sclerosis and future challenges.

Perit Dial Int 2005; 25(Suppl 4): S77–82.

35.

Sampimon

D.E.

, Coester

A.M.

, Struijk

D.G.

, Krediet

R.T.

The time course of peritoneal transport parameters in peritoneal dialysis patients who develop encapsulating peritoneal sclerosis.

Nephrol Dial Transplant 2011; 26: 291–8.

36.

Lambie

M.L.

, John

, Mushahar

, Huckvale

, Davies

S.J.

The peritoneal osmotic conductance is low well before the diagnosis of encapsulating peritoneal sclerosis is made.

Kidney Int 2010; 78: 611–18.

37.

Loureiro

, Gónzalez–Mateo

, Jimenez–Heffernan

, Selgas

, López–Cabrera

, Aguilera Peralta

Are the mesothelial-to-mesenchymal transition, sclerotic peritonitis syndromes, and encapsulating peritoneal sclerosis part of the same process?

Int J Nephrol 2013; 2013: 263285.

38.

Guest

Tamoxifen therapy for encapsulating peritoneal sclerosis: mechanism of action and update on clinical experiences.

Perit Dial Int 2009; 29: 252–5.

39.

Huang

J.W.

, Yen

C.J.

, Wu

H.Y.

, Chiang

C.K.

, Cheng

H.T.

, Lien

Y.C.

Tamoxifen downregulates connective tissue growth factor to ameliorate peritoneal fibrosis.

Blood Purif 2011; 31: 252–8.

40.

Selgas

, Aguilera

, Bajo

, Loureiro

, Del Peso

, Aroeira

Effects of tamoxifen on epithelial-to-mesenchymal transition, fibrosis and angiogenesis of mesothelial cells [Abstract].

J Am Soc Nephrol 2006; (Suppl 3): S19.

41.

Loureiro

, Sandoval

, Del Peso

, Gónzalez–Mateo

, Fernández–Millara

, Santamaria

Tamoxifen ameliorates peritoneal membrane damage by blocking mesothelial to mesenchymal transition in peritoneal dialysis.

PLoS One 2013; 8: e1165.

42.

del Peso

, Bajo

M.A.

, Gil

, Aguilera

, Ros

, Costero

Clinical experience with tamoxifen in peritoneal fibrosing syndromes.

Adv Perit Dial 2003; 19: 32–5.

43.

Summers

A.M.

, Abrahams

A.C.

, Alscher

M.D.

, Betjes

, Boeschoten

E.W.

, Braun

A collaborative approach to understanding EPS: the European perspective.

Perit Dial Int 2011; 31: 245–8.

44.

Dunn

W.B.

, Summers

, Brown

, Goodacre

, Lambie

, Johnson

Proof-of-principle study to detect metabolic changes in peritoneal dialysis effluent in patients who develop encapsulating peritoneal sclerosis.

Nephrol Dial Transplant 2012; 27: 2502–10.

45.

Kawanishi

, Nakayama

, Miyazaki

, Honda

, Tomo

, Kasai

Prospective multicenter observational study of encapsulating peritoneal sclerosis with neutral dialysis solution—the NEXT-PD study.

Adv Perit Dial 2010; 26: 71–4.

Can EPS Development be Avoided with Early Interventions? The Potential Role of Tamoxifen—A Single-Center Study

Abstract

Background

Methods

Results

Conclusions

Keywords

Get full access to this article

References